We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva's OpenData to Help Servier Build a Global AI Data Foundation
Read MoreHide Full Article
Key Takeaways
Veeva OpenData will standardize Servier's customer reference data across more than 80 countries.
Servier's deployment could deepen Veeva's role in AI, analytics and commercial engagement.
OpenData, Link and Compass give Veeva a broader platform for customers' evolving data needs.
Veeva Systems (VEEV - Free Report) recently announced that Servier has selected Veeva OpenData to standardize customer reference data across more than 80 countries. The move strengthens Veeva’s position as a key provider of data solutions for global life sciences companies.
The deal underscores growing demand for high-quality, connected data as pharmaceutical companies look to scale artificial intelligence and advanced analytics. Servier’s broad global deployment also highlights the potential for Veeva to deepen its footprint within large life sciences organizations, supporting recurring revenue opportunities and long-term growth in its Data Cloud business.
Likely Trend of VEEV Stock Following the News
Following the announcement on Sept. 30, shares of VEEV traded flat on Friday. Year to date, shares of the company have gained 22.4% compared with the industry’s 18.1% growth. However, the S&P 500 has risen 12.3% in the same timeframe.
Servier’s global adoption of Veeva OpenData could support Veeva’s long-term growth by expanding the strategic role of its Data Cloud portfolio within large pharmaceutical organizations. As life sciences companies increasingly invest in AI, analytics and personalized commercial engagement, the need for standardized, connected and reliable data is likely to grow.
Servier’s deployment across more than 80 countries also provides Veeva with an opportunity to deepen its relationship with a major global customer and potentially drive broader adoption of its data and commercial solutions. Over time, such wins could strengthen Veeva’s recurring revenue base, increase customer stickiness and reinforce its competitive position in the growing life sciences data market.
VEEV currently has a market capitalization of $44.25 billion.
Image Source: Zacks Investment Research
Servier Expands Use of Veeva’s Data Solutions
Servier’s adoption of Veeva OpenData expands its relationship with Veeva by standardizing customer reference data across more than 80 countries, creating a consistent data foundation for its global operations. Building on its use of Veeva Link Key People, the deployment is expected to improve data consistency, connect customer information with actionable insights and support more targeted commercial and medical engagement. The move also reflects growing demand among pharmaceutical companies for scalable data infrastructure to support AI and advanced analytics.
Veeva’s Data Cloud Portfolio
Veeva’s Data Cloud brings together several data products designed to help life sciences companies access connected, standardized and actionable information. The portfolio includes Veeva OpenData, Veeva Link and Veeva Compass, with each product addressing different aspects of the data requirements of pharmaceutical and other life sciences organizations.
Veeva OpenData provides standardized customer reference data, helping companies maintain accurate and consistent information on healthcare professionals and organizations across markets. By reducing fragmented data sources and establishing a common data foundation, OpenData can support more reliable downstream analytics, commercial applications and AI initiatives.
Veeva Link complements OpenData by providing connected intelligence around healthcare professionals and other life sciences stakeholders. Its Link Key People offering helps commercial and medical teams identify and understand key individuals, enabling them to access relevant insights and improve engagement strategies. Servier’s use of Link Key People alongside OpenData illustrates how Veeva’s products can work together to connect foundational customer data with actionable intelligence.
Veeva Compass adds another layer to the Data Cloud portfolio by providing healthcare data and insights that can help life sciences companies understand market dynamics and commercial opportunities. Together, OpenData, Link and Compass give Veeva a broader platform through which it can address customers’ evolving data requirements. This integrated approach could strengthen Veeva’s competitive positioning as pharmaceutical companies increasingly prioritize data quality, advanced analytics and AI-enabled commercial execution.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
Recently, Veeva expanded its AI strategy with the launch of Falcon Router, a new agentic solution designed to help biopharma companies streamline the intake and routing of safety, quality and medical cases across reporting channels. The offering, scheduled for early adopter availability in January 2027, adds to Veeva's growing Falcon Agent Suite aimed at automating industry-specific workflows.
Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Veeva's OpenData to Help Servier Build a Global AI Data Foundation
Key Takeaways
Veeva Systems (VEEV - Free Report) recently announced that Servier has selected Veeva OpenData to standardize customer reference data across more than 80 countries. The move strengthens Veeva’s position as a key provider of data solutions for global life sciences companies.
The deal underscores growing demand for high-quality, connected data as pharmaceutical companies look to scale artificial intelligence and advanced analytics. Servier’s broad global deployment also highlights the potential for Veeva to deepen its footprint within large life sciences organizations, supporting recurring revenue opportunities and long-term growth in its Data Cloud business.
Likely Trend of VEEV Stock Following the News
Following the announcement on Sept. 30, shares of VEEV traded flat on Friday. Year to date, shares of the company have gained 22.4% compared with the industry’s 18.1% growth. However, the S&P 500 has risen 12.3% in the same timeframe.
Servier’s global adoption of Veeva OpenData could support Veeva’s long-term growth by expanding the strategic role of its Data Cloud portfolio within large pharmaceutical organizations. As life sciences companies increasingly invest in AI, analytics and personalized commercial engagement, the need for standardized, connected and reliable data is likely to grow.
Servier’s deployment across more than 80 countries also provides Veeva with an opportunity to deepen its relationship with a major global customer and potentially drive broader adoption of its data and commercial solutions. Over time, such wins could strengthen Veeva’s recurring revenue base, increase customer stickiness and reinforce its competitive position in the growing life sciences data market.
VEEV currently has a market capitalization of $44.25 billion.
Image Source: Zacks Investment Research
Servier Expands Use of Veeva’s Data Solutions
Servier’s adoption of Veeva OpenData expands its relationship with Veeva by standardizing customer reference data across more than 80 countries, creating a consistent data foundation for its global operations. Building on its use of Veeva Link Key People, the deployment is expected to improve data consistency, connect customer information with actionable insights and support more targeted commercial and medical engagement. The move also reflects growing demand among pharmaceutical companies for scalable data infrastructure to support AI and advanced analytics.
Veeva’s Data Cloud Portfolio
Veeva’s Data Cloud brings together several data products designed to help life sciences companies access connected, standardized and actionable information. The portfolio includes Veeva OpenData, Veeva Link and Veeva Compass, with each product addressing different aspects of the data requirements of pharmaceutical and other life sciences organizations.
Veeva OpenData provides standardized customer reference data, helping companies maintain accurate and consistent information on healthcare professionals and organizations across markets. By reducing fragmented data sources and establishing a common data foundation, OpenData can support more reliable downstream analytics, commercial applications and AI initiatives.
Veeva Link complements OpenData by providing connected intelligence around healthcare professionals and other life sciences stakeholders. Its Link Key People offering helps commercial and medical teams identify and understand key individuals, enabling them to access relevant insights and improve engagement strategies. Servier’s use of Link Key People alongside OpenData illustrates how Veeva’s products can work together to connect foundational customer data with actionable intelligence.
Veeva Compass adds another layer to the Data Cloud portfolio by providing healthcare data and insights that can help life sciences companies understand market dynamics and commercial opportunities. Together, OpenData, Link and Compass give Veeva a broader platform through which it can address customers’ evolving data requirements. This integrated approach could strengthen Veeva’s competitive positioning as pharmaceutical companies increasingly prioritize data quality, advanced analytics and AI-enabled commercial execution.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
Recently, Veeva expanded its AI strategy with the launch of Falcon Router, a new agentic solution designed to help biopharma companies streamline the intake and routing of safety, quality and medical cases across reporting channels. The offering, scheduled for early adopter availability in January 2027, adds to Veeva's growing Falcon Agent Suite aimed at automating industry-specific workflows.
VEEV’s Zacks Rank & Key Picks
Currently, VEEV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.